Antidepressants for Major Depressive Disorder: Drug Information to Support Drug Therapy Decisions

B.C. Provincial Academic Detailing (PAD) Service March 2020

References

Page 1: Background


Page 2: Evidence

27. US Food and Drug Administration. Drugs@FDA. Celexa (citalopram). https://www.accessdata.fda.gov/scripts/cder/daf/
34. US Food and Drug Administration. Drugs@FDA. Paxil (paroxetine). https://www.accessdata.fda.gov/scripts/cder/daf/
41. US Food and Drug Administration. Drugs@FDA. Trintellix (vortioxetine). https://www.accessdata.fda.gov/scripts/cder/daf/
47. US Food and Drug Administration. Drugs@FDA. Cymbalta (duloxetine). https://www.accessdata.fda.gov/scripts/cder/daf/
49. US Food and Drug Administration. Drugs@FDA. Fetzima (levomilnacipran). https://www.accessdata.fda.gov/scripts/cder/daf/
52. US Food and Drug Administration. Drugs@FDA. Remeron (mirtazapine). https://www.accessdata.fda.gov/scripts/cder/daf/
27. US Food and Drug Administration. Drugs@FDA. Fetzima (levomilnacipran). https://www.accessdata.fda.gov/scripts/cder/daf/
34. US Food and Drug Administration. Drugs@FDA. Wellbutrin XL (bupropion extended release). https://www.accessdata.fda.gov/scripts/cder/daf/


58. BC Centre for Disease Control. Venlafaxine: troubling toxicity in overdose. BCMJ 2007;49:10


64. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019;97:111-21


Page 6: Drug Interaction Table

1. Indiana University. Drug Interactions Flockhart Table. [Internet]. https://drug-interactions.medicine.iu.edu/MainTable.aspx
Page 7: Antidepressant Withdrawal and Tapering

1. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav 2019;97:111-121
Page 8: Discussion

6. Turner E, Rosenthal R. Efficacy of antidepressants. Is not an absolute measure, and it depends on how clinical significance is defined. BMJ 2008;336:516-7